Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.40
MDT's Cash to Debt is ranked lower than
79% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. MDT: 0.40 )
Ranked among companies with meaningful Cash to Debt only.
MDT' s Cash to Debt Range Over the Past 10 Years
Min: 0.21  Med: 0.79 Max: 7.76
Current: 0.4
0.21
7.76
Equity to Asset 0.52
MDT's Equity to Asset is ranked lower than
67% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. MDT: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
MDT' s Equity to Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.56 Max: 0.79
Current: 0.52
0.48
0.79
Interest Coverage 3.82
MDT's Interest Coverage is ranked lower than
86% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 38.74 vs. MDT: 3.82 )
Ranked among companies with meaningful Interest Coverage only.
MDT' s Interest Coverage Range Over the Past 10 Years
Min: 3.82  Med: 11.01 Max: 28.15
Current: 3.82
3.82
28.15
F-Score: 4
Z-Score: 2.96
M-Score: -2.38
WACC vs ROIC
7.87%
6.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 18.35
MDT's Operating margin (%) is ranked higher than
88% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 2.65 vs. MDT: 18.35 )
Ranked among companies with meaningful Operating margin (%) only.
MDT' s Operating margin (%) Range Over the Past 10 Years
Min: 17.77  Med: 24.23 Max: 30.17
Current: 18.35
17.77
30.17
Net-margin (%) 12.27
MDT's Net-margin (%) is ranked higher than
81% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. MDT: 12.27 )
Ranked among companies with meaningful Net-margin (%) only.
MDT' s Net-margin (%) Range Over the Past 10 Years
Min: 12.27  Med: 18.73 Max: 22.78
Current: 12.27
12.27
22.78
ROE (%) 6.77
MDT's ROE (%) is ranked higher than
62% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. MDT: 6.77 )
Ranked among companies with meaningful ROE (%) only.
MDT' s ROE (%) Range Over the Past 10 Years
Min: 6.72  Med: 19.60 Max: 27.52
Current: 6.77
6.72
27.52
ROA (%) 3.41
MDT's ROA (%) is ranked higher than
62% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: -0.01 vs. MDT: 3.41 )
Ranked among companies with meaningful ROA (%) only.
MDT' s ROA (%) Range Over the Past 10 Years
Min: 3.43  Med: 10.41 Max: 14.3
Current: 3.41
3.43
14.3
ROC (Joel Greenblatt) (%) 59.45
MDT's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 4.86 vs. MDT: 59.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 51.21  Med: 68.27 Max: 82.85
Current: 59.45
51.21
82.85
Revenue Growth (3Y)(%) 7.80
MDT's Revenue Growth (3Y)(%) is ranked higher than
68% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. MDT: 7.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.2  Med: 12.60 Max: 18.2
Current: 7.8
4.2
18.2
EBITDA Growth (3Y)(%) 5.60
MDT's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. MDT: 5.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MDT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.7  Med: 11.60 Max: 32.5
Current: 5.6
-0.7
32.5
EPS Growth (3Y)(%) -9.70
MDT's EPS Growth (3Y)(%) is ranked lower than
69% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. MDT: -9.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MDT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.7  Med: 13.60 Max: 26.5
Current: -9.7
-9.7
26.5
» MDT's 10-Y Financials

Financials (Next Earnings Date: 2016-08-25)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MDT Guru Trades in Q3 2015

Joel Greenblatt 10,247 sh (New)
Paul Tudor Jones 151,700 sh (New)
Manning & Napier Advisors, Inc 2,671,920 sh (New)
Jim Simons 531,441 sh (New)
First Eagle Investment 17,735 sh (+39.26%)
Vanguard Health Care Fund 20,081,233 sh (+6.33%)
Ruane Cunniff 5,075 sh (+4.00%)
John Buckingham 21,140 sh (+3.85%)
Pioneer Investments 2,451,935 sh (+3.16%)
Robert Olstein 134,000 sh (unchged)
John Keeley 40,520 sh (unchged)
Bill Nygren 4,190,000 sh (unchged)
David Carlson 830,000 sh (unchged)
John Hussman 175,000 sh (unchged)
Steven Romick Sold Out
First Pacific Advisors Sold Out
John Burbank Sold Out
Jeff Auxier 139,473 sh (-0.08%)
Ronald Muhlenkamp 173,364 sh (-0.22%)
Mairs and Power 3,171,922 sh (-1.29%)
Barrow, Hanley, Mewhinney & Strauss 30,967,127 sh (-2.05%)
Diamond Hill Capital 3,466,464 sh (-2.37%)
Jeremy Grantham 7,197,272 sh (-4.62%)
HOTCHKIS & WILEY 5,290,450 sh (-5.86%)
PRIMECAP Management 15,260,876 sh (-6.92%)
Ken Fisher 5,939 sh (-7.85%)
Dodge & Cox 6,971,380 sh (-12.99%)
Steven Cohen 500,900 sh (-16.01%)
Mario Gabelli 46,079 sh (-30.13%)
Ray Dalio 57,186 sh (-32.83%)
» More
Q4 2015

MDT Guru Trades in Q4 2015

Louis Moore Bacon 375,000 sh (New)
First Eagle Investment 1,940,036 sh (+10839.02%)
Manning & Napier Advisors, Inc 5,016,210 sh (+87.74%)
Pioneer Investments 4,269,571 sh (+74.13%)
David Carlson 900,000 sh (+8.43%)
John Buckingham 22,788 sh (+7.80%)
Bill Nygren 4,190,000 sh (unchged)
Vanguard Health Care Fund 20,081,233 sh (unchged)
Ruane Cunniff 5,075 sh (unchged)
John Hussman 175,000 sh (unchged)
Ronald Muhlenkamp Sold Out
Jim Simons Sold Out
Jeff Auxier 139,273 sh (-0.14%)
PRIMECAP Management 15,187,651 sh (-0.48%)
Ken Fisher 5,905 sh (-0.57%)
Diamond Hill Capital 3,436,197 sh (-0.87%)
Mairs and Power 3,143,155 sh (-0.91%)
Dodge & Cox 6,867,935 sh (-1.48%)
Barrow, Hanley, Mewhinney & Strauss 30,282,119 sh (-2.21%)
Ray Dalio 53,186 sh (-6.99%)
Steven Cohen 461,800 sh (-7.81%)
Mario Gabelli 40,111 sh (-12.95%)
Robert Olstein 108,000 sh (-19.40%)
HOTCHKIS & WILEY 3,880,914 sh (-26.64%)
Jeremy Grantham 4,545,540 sh (-36.84%)
John Keeley 25,281 sh (-37.61%)
Joel Greenblatt 2,705 sh (-73.60%)
Paul Tudor Jones 3,200 sh (-97.89%)
» More
Q1 2016

MDT Guru Trades in Q1 2016

Signature Select Canadian Fund 126,900 sh (New)
George Soros 11,100 sh (New)
Manning & Napier Advisors, Inc 7,795,870 sh (+55.41%)
Pioneer Investments 4,619,992 sh (+8.21%)
David Carlson 930,000 sh (+3.33%)
John Buckingham 23,323 sh (+2.35%)
Jeff Auxier 139,773 sh (+0.36%)
PRIMECAP Management 15,196,981 sh (+0.06%)
John Hussman 175,000 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
Joel Greenblatt Sold Out
Ray Dalio Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
Dodge & Cox 6,838,035 sh (-0.44%)
Mairs and Power 3,017,700 sh (-3.99%)
First Eagle Investment 1,833,793 sh (-5.48%)
Mario Gabelli 37,877 sh (-5.57%)
Vanguard Health Care Fund 18,332,133 sh (-8.71%)
Barrow, Hanley, Mewhinney & Strauss 27,494,507 sh (-9.21%)
Robert Olstein 96,000 sh (-11.11%)
Ken Fisher 5,018 sh (-15.02%)
Jeremy Grantham 3,706,658 sh (-18.46%)
Ruane Cunniff 3,895 sh (-23.25%)
Diamond Hill Capital 2,515,263 sh (-26.80%)
HOTCHKIS & WILEY 2,374,011 sh (-38.83%)
Bill Nygren 2,490,000 sh (-40.57%)
John Keeley 12,172 sh (-51.85%)
» More
Q2 2016

MDT Guru Trades in Q2 2016

T Rowe Price Equity Income Fund 750,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:ABT, NYSE:SYK, NYSE:BSX, NAS:ISRG, NYSE:ZBH, NYSE:STJ, NYSE:EW, NYSE:SNN, OTCPK:SONVY, NYSE:VAR, NYSE:TFX, NAS:ALGN, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:WILLF, NAS:ABMD, OTCPK:FSPKF, NAS:NUVA, OTCPK:EKTAY, NAS:IART » details
Traded in other countries:MDT.Argentina, MDTC34.Brazil, 2M6.Germany, MDT N.Mexico, MDT.Switzerland, 0QYG.UK,
Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in three operating segments that manufacture and sell device-based medical therapies.

Medtronic PLC was founded in 1949, incorporated as a Minnesota corporation in 1957. The Company is a medical technology company - alleviating pain, restoring health, and extending life for millions of people around the world. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat and diabetes conditions. The Company functions in four operating segments that manufacture and sell device-based medical therapies: Cardiac and Vascular Group; Minimally Invasive Therapies Group; Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group includes Cardiac Rhythm Disease Management that develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRDM devices, and an integrated health solutions business; Coronary which includes therapies to treat coronary artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, including a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories; The Structural Heart business offers a comprehensive line of products and therapies to treat a variety of heart valve disorders. The Endovascular business is comprised of a comprehensive line of products and therapies to treat aortic disease (such as aneurysms, dissections, and transections) as well as peripheral vascular disease (PVD). Its products include endovascular stent graft systems, peripheral stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart. The Minimally Invasive Therapies Group is composed of the Surgical Solutions and Patient Monitoring & Recovery divisions. With a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications, the group looks to enhance patient outcomes through minimally invasive solutions. The Restorative Therapies Group includes Spine business which develops, manufactures, and markets a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its products and therapies treat a variety of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumors, fractures of the spine, and stenosis. Its Spine business also provides biologic solutions for the orthopedic and dental markets. Its Neuromodulation business includes implantable neurostimulation and targeted drug delivery systems for the management of ch

Guru Investment Theses on Medtronic PLC

Bill Frels Comments on Medtronic Inc - Oct 20, 2014

Healthcare company Medtronic, Inc. (MDT) detracted slightly from performance during the period. Pending a shareholder vote later this year or in 2015, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Your Growth Fund portfolio managers are pleased to report that we have completed our valuation for Medtronic. As of October 7, 2014 we believe combined Medtronic/Covidien to be $8 per share more valuable than shares of Medtronic alone.

As of September 30, 2014, the market value of the Growth Fund’s holding in Medtronic was $24 per share greater than its cost basis. We estimate that our typical shareholder, that holds the Growth Fund in a taxable amount, will experience about a $6.00 per share tax liability. We do not offer tax advice; each shareholder should consult a tax advisor about his/her particular circumstance. Providing that there are no significant changes, our current thinking leads us to believe that voting for the merger is in our shareholders’ best interest. We will keep you posted as the voting date is finalized or if we learn of any other developments regarding the merger plans.

From Bill Frels (Trades, Portfolio)' Mairs & Power Growth Fund Q3 2014 Commentary.

Check out Bill Frels latest stock trades

Bill Frels Comments on Medtronic Inc - Jul 31, 2014

Healthcare company Medtronic, Inc. (MDT) also contributed to performance, gaining 3.61% and 11.10% for the second quarter and first six months, respectively. Pending a shareholder vote later this year or in 2015, however, Medtronic is expected to merge with medical device supplier Covidien Plc and change its legal domicile to Ireland. Once completed, the merger will create a taxable event for Fund shareholders who will realize a long-term capital gain estimated at $60 million or $1.50 a share.

From Bill Frels (Trades, Portfolio)’ Mairs & Power Growth Fund Second Quarter 2014 Commentary.

Check out Bill Frels latest stock trades

Top Ranked Articles about Medtronic PLC

T Rowe Price Buys Apple and 2 Other Companies Equity income fund reports its 2nd-quarter portfolio
The “father of growth investing,” Thomas Rowe Price founded the T Rowe Price Equity Income Fund October 1985. While Price prefers a growth-oriented approach to investing, the equity income fund invests in stocks using a “conservative, value-oriented” approach. According to its investment strategy, the fund emphasizes strong dividend payout and undervaluation. With this approach, the mutual fund can reduce its risk more than just investing in growth stocks. Read more...
IBM's CEO Discusses Cognitive Computing Under Armour, Medtronic and Softbank give examples of Watson applications
IBM (NYSE:IBM) CEO Ginni Rometty discussed Watson, IBM’s artificial intelligence platform, at this year’s Consumer Electronics Show in January. In the video below, she asserts that the future of the internet is cognitive. The goal of Watson is to help customers make better decisions by collecting massive amounts of data for predictive analytics. Three business leaders from Under Armour (NYSE:UA), Medtronic (NYSE:MDT) and Softbank (SFTBY) discuss how they are incorporating Watson’s functionality into their products and services. The video does a good job of describing IBM’s vision and business strategy. The company has had four straight years of revenue declines, and investors are wondering when new revenue streams will offset the declines in their existing businesses. Read more...
Ronald Muhlenkamp Sells Stakes in Medtronic and State Street Guru invests in ETF in 4th quarter
Ronald Muhlenkamp (Trades, Portfolio), founder and president of Muhlenkamp & Co. Inc. and portfolio manager for its mutual fund, acquired half a dozen new holdings in the fourth quarter, but his biggest transactions were divestitures. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 35.27
MDT's P/E(ttm) is ranked lower than
65% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 28.34 vs. MDT: 35.27 )
Ranked among companies with meaningful P/E(ttm) only.
MDT' s P/E(ttm) Range Over the Past 10 Years
Min: 10.17  Med: 20.64 Max: 54.09
Current: 35.27
10.17
54.09
Forward P/E 18.80
MDT's Forward P/E is ranked higher than
80% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 24.63 vs. MDT: 18.80 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 35.27
MDT's PE(NRI) is ranked lower than
63% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 28.88 vs. MDT: 35.27 )
Ranked among companies with meaningful PE(NRI) only.
MDT' s PE(NRI) Range Over the Past 10 Years
Min: 10.17  Med: 20.64 Max: 54.09
Current: 35.27
10.17
54.09
Price/Owner Earnings (ttm) 29.12
MDT's Price/Owner Earnings (ttm) is ranked higher than
57% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.52 vs. MDT: 29.12 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MDT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.24  Med: 19.19 Max: 96.77
Current: 29.12
9.24
96.77
P/B 2.32
MDT's P/B is ranked higher than
61% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.95 vs. MDT: 2.32 )
Ranked among companies with meaningful P/B only.
MDT' s P/B Range Over the Past 10 Years
Min: 1.78  Med: 2.99 Max: 6.52
Current: 2.32
1.78
6.52
P/S 4.31
MDT's P/S is ranked lower than
59% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 3.51 vs. MDT: 4.31 )
Ranked among companies with meaningful P/S only.
MDT' s P/S Range Over the Past 10 Years
Min: 1.93  Med: 3.50 Max: 6.69
Current: 4.31
1.93
6.69
PFCF 29.91
MDT's PFCF is ranked higher than
52% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 31.08 vs. MDT: 29.91 )
Ranked among companies with meaningful PFCF only.
MDT' s PFCF Range Over the Past 10 Years
Min: 9.19  Med: 14.84 Max: 70.23
Current: 29.91
9.19
70.23
POCF 23.92
MDT's POCF is ranked lower than
56% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 20.58 vs. MDT: 23.92 )
Ranked among companies with meaningful POCF only.
MDT' s POCF Range Over the Past 10 Years
Min: 8.14  Med: 12.92 Max: 32.42
Current: 23.92
8.14
32.42
EV-to-EBIT 24.54
MDT's EV-to-EBIT is ranked lower than
54% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 22.17 vs. MDT: 24.54 )
Ranked among companies with meaningful EV-to-EBIT only.
MDT' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 15.80 Max: 30.9
Current: 24.54
8.7
30.9
EV-to-EBITDA 16.41
MDT's EV-to-EBITDA is ranked higher than
56% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 18.09 vs. MDT: 16.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.4  Med: 13.30 Max: 24.9
Current: 16.41
7.4
24.9
PEG 10.03
MDT's PEG is ranked lower than
82% of the 74 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. MDT: 10.03 )
Ranked among companies with meaningful PEG only.
MDT' s PEG Range Over the Past 10 Years
Min: 1.1  Med: 1.92 Max: 18.15
Current: 10.03
1.1
18.15
Shiller P/E 30.68
MDT's Shiller P/E is ranked higher than
71% of the 45 Companies
in the Global Medical Devices industry.

( Industry Median: 41.87 vs. MDT: 30.68 )
Ranked among companies with meaningful Shiller P/E only.
MDT' s Shiller P/E Range Over the Past 10 Years
Min: 14.49  Med: 22.27 Max: 44.51
Current: 30.68
14.49
44.51
Current Ratio 3.29
MDT's Current Ratio is ranked higher than
60% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.83 vs. MDT: 3.29 )
Ranked among companies with meaningful Current Ratio only.
MDT' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.45 Max: 4.52
Current: 3.29
0.88
4.52
Quick Ratio 2.81
MDT's Quick Ratio is ranked higher than
63% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. MDT: 2.81 )
Ranked among companies with meaningful Quick Ratio only.
MDT' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 2.03 Max: 4.09
Current: 2.81
0.69
4.09
Days Inventory 138.88
MDT's Days Inventory is ranked lower than
52% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 134.88 vs. MDT: 138.88 )
Ranked among companies with meaningful Days Inventory only.
MDT' s Days Inventory Range Over the Past 10 Years
Min: 132.14  Med: 142.57 Max: 164.01
Current: 138.88
132.14
164.01
Days Sales Outstanding 70.41
MDT's Days Sales Outstanding is ranked lower than
53% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 68.74 vs. MDT: 70.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.41  Med: 81.90 Max: 92.09
Current: 70.41
70.41
92.09
Days Payable 68.23
MDT's Days Payable is ranked higher than
56% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 62.25 vs. MDT: 68.23 )
Ranked among companies with meaningful Days Payable only.
MDT' s Days Payable Range Over the Past 10 Years
Min: 32.49  Med: 50.36 Max: 93.14
Current: 68.23
32.49
93.14

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.80
MDT's Dividend Yield is ranked higher than
62% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 1.58 vs. MDT: 1.80 )
Ranked among companies with meaningful Dividend Yield only.
MDT' s Dividend Yield Range Over the Past 10 Years
Min: 0.61  Med: 1.86 Max: 2.93
Current: 1.8
0.61
2.93
Dividend Payout 0.61
MDT's Dividend Payout is ranked lower than
77% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 0.34 vs. MDT: 0.61 )
Ranked among companies with meaningful Dividend Payout only.
MDT' s Dividend Payout Range Over the Past 10 Years
Min: 0.17  Med: 0.27 Max: 0.61
Current: 0.61
0.17
0.61
Dividend Growth (3y) 13.50
MDT's Dividend Growth (3y) is ranked higher than
61% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. MDT: 13.50 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MDT' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7.6  Med: 14.90 Max: 24.9
Current: 13.5
7.6
24.9
Forward Dividend Yield 1.97
MDT's Forward Dividend Yield is ranked higher than
65% of the 158 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. MDT: 1.97 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.93
MDT's Yield on cost (5-Year) is ranked higher than
71% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. MDT: 2.93 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MDT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.99  Med: 3.02 Max: 4.76
Current: 2.93
0.99
4.76
3-Year Average Share Buyback Ratio -11.30
MDT's 3-Year Average Share Buyback Ratio is ranked lower than
72% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: -3.30 vs. MDT: -11.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.3  Med: 1.00 Max: 2.5
Current: -11.3
-11.3
2.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.42
MDT's Price/Projected FCF is ranked higher than
71% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. MDT: 1.42 )
Ranked among companies with meaningful Price/Projected FCF only.
MDT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.78  Med: 1.40 Max: 6.95
Current: 1.42
0.78
6.95
Price/DCF (Earnings Based) 3.29
MDT's Price/DCF (Earnings Based) is ranked lower than
80% of the 20 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. MDT: 3.29 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.24
MDT's Price/Median PS Value is ranked lower than
63% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. MDT: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
MDT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.49 Max: 3.61
Current: 1.24
0.71
3.61
Earnings Yield (Greenblatt) (%) 4.10
MDT's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 341 Companies
in the Global Medical Devices industry.

( Industry Median: -0.40 vs. MDT: 4.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.2  Med: 6.30 Max: 11.5
Current: 4.1
3.2
11.5
Forward Rate of Return (Yacktman) (%) 8.08
MDT's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 117 Companies
in the Global Medical Devices industry.

( Industry Median: 7.42 vs. MDT: 8.08 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MDT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.2  Med: 14.80 Max: 20.6
Current: 8.08
7.2
20.6

More Statistics

Revenue (TTM) (Mil) $28,833
EPS (TTM) $ 2.48
Beta1.01
Short Percentage of Float1.13%
52-Week Range $55.54 - 89.27
Shares Outstanding (Mil)1,394.73

Analyst Estimate

Apr17 Apr18 Apr19
Revenue (Mil $) 29,949 31,478 33,875
EPS ($) 4.66 5.15 5.86
EPS w/o NRI ($) 4.66 5.15 5.86
EPS Growth Rate
(3Y to 5Y Estimate)
7.60%
Dividends Per Share ($) 1.67 1.92 2.31
» More Articles for MDT

Headlines

Articles On GuruFocus.com
T. Rowe Price Buys Apple, Pepsi, Western Digital Jul 26 2016 
T. Rowe Price Ditches Domestic, Buys Foreign Jul 22 2016 
T Rowe Price Buys Apple and 2 Other Companies Jul 15 2016 
Baxter Well Positioned in Fast-Growing Market for Kidney Dialysis Equipment Jul 01 2016 
IBM's CEO Discusses Cognitive Computing Apr 10 2016 
The Conundrum in Health Care Investing Mar 06 2016 
Ronald Muhlenkamp Sells Stakes in Medtronic and State Street Feb 14 2016 
Researching United Technologies: Here’s How I Do It Feb 01 2016 
Investment Ideas Trading With Very Low P/S Ratio Jan 13 2016 
A Recession-Resistant Dividend Aristocrat With 10% Dividend Growth Jan 05 2016 

More From Other Websites
New crop of robots to vie for space in the operating room Jul 28 2016
3:18 pm Medtronic REALITY trial enrolls first patient in study evaluating Medtronic directional... Jul 27 2016
REALITY Trial Enrolls First Patient in Study Evaluating Medtronic Directional Atherectomy and... Jul 27 2016
ETF’s with exposure to Medtronic Plc : July 25, 2016 Jul 25 2016
How Did JNJ’s Medical Devices Segment Perform in 2Q16? Jul 25 2016
Medtronic Unveils VariLoc Variable Angle Locking Technology for Treatment of Fractures Jul 25 2016
[$$] Columbia Large Cap Growth Takes a Long View Jul 22 2016
Medtronic Plc :MDT-US: Earnings Analysis: 2016 By the Numbers : July 22, 2016 Jul 22 2016
Medtronic gets FDA thumbs up for latest product Jul 21 2016
Medtronic Gets First-Ever FDA Approval For Cement-Augmented Pedicle Screws Jul 20 2016
Insiders Are Fleeing IHS Markit Ltd (INFO) and Medtronic PLC (MDT), Plus Insider Buying at 3... Jul 20 2016
FDA approves Medtronic product Jul 20 2016
Medtronic Receives First-Ever FDA Clearance for Cement-Augmented Pedicle Screws Jul 20 2016
Intuitive Surgical Posts Q2 EPS, Sales Beat As Da Vinci Sales Rise Jul 19 2016
Medtronic Expands Continuous Glucose Monitoring (CGM) Solutions for People with Diabetes Using... Jul 19 2016
5 Big Medtech Stocks Investors Love Right Now -- but Should You Buy Them? Jul 19 2016
Medtronic Receives FDA Approval for Two-Level Prestige LP(TM) Cervical Disc Procedures Jul 18 2016
Medtronic Introduces Revamped Minimally Invasive Spine Fusion Procedures Jul 15 2016
Medtronic Foundation Calls for Applications for 2016 Bakken Invitation Award Jul 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)